Advertisement
Research ArticleMetabolism, Transport, and Pharmacogenomics

Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics July 2012, 342 (1) 33-40; DOI: https://doi.org/10.1124/jpet.112.192195
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleMetabolism, Transport, and Pharmacogenomics

P-gp and Bcrp Restrict Brain Distribution of Vemurafenib

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics July 1, 2012, 342 (1) 33-40; DOI: https://doi.org/10.1124/jpet.112.192195
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement